Navigation Links
Echo Therapeutics Schedules Second Quarter 2013 Financial Results for Thursday, August 8, 2013
Date:8/6/2013

Symphony CGM System, the failure of future development and preliminary marketing efforts related to Echo's Symphony CGM System, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell the Symphony CGM System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony CGM System. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2012, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:
Christine H. Olimpio                                         
Director, Investor Relations and Corporate Communications
(215) 717-4104 
colimpio@echotx.com                                         

Connect With Us:
- Visit our website at www.echotx.com
- Follow us on Twitter at www.twitter.com/echotx
- Join us on Facebook at <
'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Prime Therapeutics adds 80 new jobs in Albuquerque
2. Lightlake Therapeutics Retains KCSA Strategic Communications as Corporate Communications Advisors
3. PTC Therapeutics To Host Second Quarter 2013 Financial Results Conference Call And Webcast
4. Cell Therapeutics Reports Second Quarter 2013 Financial Results
5. AuraSense Therapeutics Closes Tranche II of Series B Equity Investment
6. Covington Advises Actelion in Acquisition of Ceptaris Therapeutics
7. Oncos Therapeutics Granted Orphan Drug Designation for CGTG-102 in Soft Tissue Sarcoma (STS) by FDA and EMA
8. Diabetes Therapeutics Market in India to 2018 - Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Drive Growth
9. Serina Therapeutics Announces Agreement with the Scripps Research Institute for Development of Polymer-Antibody Drug Conjugates
10. Advanced Prenatal Therapeutics Appoints Dr. Nihar Nayak to its Scientific Advisory Board
11. Signature Therapeutics Receives BrIDGs Award to Advance Its Abuse-Deterrent Oxycodone, PF614
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 IRIDEX Corporation (NASDAQ: ... James H. Mackaness is scheduled to make an investor ... at 2:55 p.m. Eastern Time on Wednesday, September 3, in ... of the investor presentation will be available in the Investors ... About IRIDEX IRIDEX Corporation was founded ...
(Date:8/27/2014)... Aug. 27, 2014   Auxilium Pharmaceuticals , Inc. (NASDAQ: ... company, today announced that certain members of the executive ... Conference to be held September 8-10, 2014 in ... Chief Executive Officer and President, is scheduled to present ... at 10:55 a.m. ET on Wednesday, September 10, 2014. ...
(Date:8/27/2014)... 27, 2014 Asterias Biotherapeutics Inc. (OTCBB: ASTY) ... Administration (FDA) to initiate a Phase 1/2a clinical trial ... spinal cord injury.  The approved trial follows the successful ... product, and is designed to assess safety and activity ... cervical spinal cord injuries, the first targeted indication for ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 2Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 4Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 5
(Date:8/27/2014)... August 27, 2014 Scientists at The Scripps ... a specific signaling pathway can be associated with alcohol ... a gene, called neurofibromatosis type 1 (Nf1), which TSRI ... The new research shows Nf1 regulates gamma-aminobutyric acid (GABA), ... relaxation. , "This novel and seminal study provides ...
(Date:8/27/2014)... Georgia State University’s Center for ... $600,000 grant from the Maternal and Child Health ... to support implementation of the Autism Plan for ... youth with autism spectrum disorder. , In preparing ... Advisory Council composed of key stakeholders from across ...
(Date:8/27/2014)... Foundation scientists examined the implications for cultural diversity ... rehabilitation. The article by Anthony Lequerica, PhD, and ... acquired brain injury (ABI) rehabilitation (doi:10.3233/NRE-141079) was ... and Krch are research scientists in Traumatic Brain ... for the Northern New Jersey TBI Model System. ...
(Date:8/27/2014)... significantly improve musculoskeletal and overall health, and minimize or ... of the latest research on senior athletes (ages 65 ... Journal of the American Academy of Orthopaedic Surgeons ... aging causes an inevitable deterioration of the body and ... of related injuries such as sprains, strains and fractures; ...
(Date:8/27/2014)... Will Holbrook, CP LP, has joined ... over 15 years of experience in the prosthetics field. ... with a Bachelor of Science degree with a major ... received his graduate degree in prosthetics at Northwestern University ... Will join us at Fourroux,” says Keith Watson, owner ...
Breaking Medicine News(10 mins):Health News:Scripps Research Institute scientists link alcohol-dependence gene to neurotransmitter 2Health News:Center for Leadership in Disability Awarded $600,000 Grant to Improve Services for Georgia’s Children and Youth with Autism 2Health News:Lifetime of fitness: A fountain of youth for bone and joint health? 2
... implants created using stem cells can only be constructed ... before the almost inevitable need for total joint replacement. ... investigating the possibilities of a biologically-engineered synthetic liquid polymer ... offering a one stop, permanent solution. ...
... caregivers to hospital patients, coordinating and providing direct care and delivering ... ensure that each of its patient-care units has an adequate number ... number of hours nurses work known as the "target level" ... flow of patients and their need for care. Too many nurses ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, March ... target levels in a large hospital, more patients died, a ... an era of nursing shortages and cost-cutting, in that the ... authors of the research, appearing in the March 17 issue ...
... By Amanda Gardner HealthDay Reporter , ... the tsunami that devastated the nuclear complex in Japan ... that any radiation from the unfolding disaster across the ... say. The chances of any radioactive plume reaching ...
... Gardner HealthDay Reporter , WEDNESDAY, March 16 (HealthDay ... treatment to show a benefit for women with a rare ... even a treatment. The drug, sirolimus (Rapamycin), improved both ... lymphangioleiomyomatosis, or LAM, according to a study published online March ...
... recent study from North Carolina State University shows that while ... has grown, fund support for park operations has been significantly ... growth endangers the more than $20 billion in economic impact ... the reduction in general-fund support for operations puts stress on ...
Cached Medicine News:Health News:Liquid biomaterials take stem cell therapy to new level 2Health News:Risk of hospital patient mortality increases with nurse staffing shortfalls, study finds 2Health News:Risk of hospital patient mortality increases with nurse staffing shortfalls, study finds 3Health News:When Nurse Staffing Drops, Mortality Rates Rise: Study 2Health News:Radiation From Japan's Nuke Disaster Unlikely to Threaten U.S., Experts Say 2Health News:Radiation From Japan's Nuke Disaster Unlikely to Threaten U.S., Experts Say 3Health News:Radiation From Japan's Nuke Disaster Unlikely to Threaten U.S., Experts Say 4Health News:Transplant Drug May Fight Rare Lung Disorder 2Health News:Transplant Drug May Fight Rare Lung Disorder 3Health News:Study shows attendance at state parks grows, even as funding decreases 2
... ultra versatile model angulates for vascular ... the height of the support leg, ... post, or double tee foot. Add ... comfort and stability. A convenient bracket ...
... RX600 is a versatile, fully powered orthopaedic ... built-in traction facilities, a powered centre break ... extremely versatile too. ,<br.,In fact the RX600 ... as it is for traction procedures. The ...
... OL1000 Bone Growth Stimulators are portable, battery-powered ... noninvasive treatment of an established nonunion fracture ... and flat bones. , ... of healing of 60.7% in patients with ...
... The EBI OsteoGen surgically implanted bone growth ... of nonunions when surgery is already planned or ... the OsteoGen is totally surgically implanted, patients are ... site 24 hours a day for up to ...
Medicine Products: